How many Intismeran autogene clinical trials are there?

10 Intismeran autogene clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 6 are actively recruiting participants.

Are Intismeran autogene clinical trials recruiting in 2026?

Yes — 6 Intismeran autogene trials are actively recruiting in 2026, with 140 U.S. sites across 34 states. See the recruiting trials and the per-state site list further down this page.

What conditions is Intismeran autogene being studied for?

Intismeran autogene is being studied for Non-small Cell Lung Cancer, Carcinoma in Situ, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Malignant Melanoma and 7 more. The trials are grouped by indication on this page.

What phase is Intismeran autogene in?

Intismeran autogene clinical trials span 4 Phase 3, 4 Phase 2. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.

Who sponsors Intismeran autogene clinical trials?

The lead sponsor across the most Intismeran autogene trials is Merck Sharp & Dohme LLC. Each trial row links to the full study detail page including sponsor information.

Intismeran autogene Clinical Trials (2026): 10 Studies for Non-small Cell Lung Cancer & Carcinoma in Situ

Creator: Hipa.ai Research
Published: 2026-06-02T17:23:04.185Z

Hipa.ai Research · Source: ClinicalTrials.gov / AACT

Synced daily from ClinicalTrials.gov via AACT. Last sync: June 18, 2026.

10 Intismeran autogene clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 9 indications (including Non-small Cell Lung Cancer & Carcinoma in Situ) and 4,709 total planned enrollment. 4 Phase 3 Intismeran autogene trials and 4 Phase 2 are listed. 6 Intismeran autogene clinical trials are actively recruiting at 140 U.S. sites across 34 states. Most recent activity: NCT07513376 (May 2038).

Where to Participate: All Intismeran autogene Trial Sites in the U.S. (140 sites across 34 states)

Every actively recruiting Intismeran autogenetrial site, sorted by state then city. Each row links to the trial detail page (eligibility, contacts, full study record). Sites no longer enrolling at the location level are excluded. ClinicalTrials.gov / AACT does not provide street-level addresses; the map link uses the facility's geocoded coordinates where available.

State	Facility	City	Trial	Map
AK	Alaska Oncology and Hematology ( Site 0039)	Anchorage99508	NCT06077760	Map
AZ	Banner MD Anderson Cancer Center ( Site 0181)	Gilbert85234	NCT06623422	Map
AZ	The University of Arizona Cancer Center - North Campus ( Site 0071)	Tucson85719	NCT06077760	Map
AZ	The University of Arizona Cancer Center - North Campus ( Site 0163)	Tucson85719	NCT06623422	Map
AR	Highlands Oncology Group ( Site 4042)	Springdale72762	NCT06961006	Map
CA	Michael G Oefelein Clinical Trials ( Site 0138)	Bakersfield93301	NCT06833073	Map
CA	Providence St. Jude Medical Center ( Site 0106)	Fullerton92835	NCT06623422	Map
CA	VA Long Beach Healthcare System ( Site 0199)	Long Beach90822	NCT06623422	Map
CA	UCLA Clinical & Translational Research Center (CTRC) ( Site 0059)	Los Angeles90095	NCT06077760	Map
CA	USC Norris Comprehensive Cancer Center ( Site 0123)	Los Angeles90033	NCT06833073	Map
CA	USC Norris Comprehensive Cancer Center ( Site 0205)	Los Angeles90033	NCT06623422	Map
CA	Hoag Memorial Hospital Presbyterian ( Site 4042)	Newport Beach92663	NCT06077760	Map
CA	Hoag Memorial Hospital Presbyterian ( Site 4048)	Newport Beach92663	NCT06077760	Map
CA	St. Joseph Hospital-The Center for Cancer Prevention and Treatment ( Site 0074)	Orange92868	NCT06077760	Map
CA	University of California, Irvine (UCI) Health - UC Irvine Medical Center ( Site 0030)	Orange92868	NCT06077760	Map
CA	UCSF Medical Center at Mission Bay ( Site 0178)	San Francisco94158	NCT06623422	Map
CA	UCSF Medical Center at Mission Bay ( Site 4044)	San Francisco94158	NCT06961006	Map
CA	Genesis Healthcare-Torrance ( Site 0140)	Torrance90503	NCT06833073	Map
CA	Genesis Research LLC ( Site 0118)	Torrance90505	NCT06833073	Map
CO	University of Colorado Anschutz Medical Campus ( Site 0151)	Aurora80045	NCT06623422	Map
CO	UCHealth Memorial Hospital Central ( Site 0125)	Colorado Springs80909	NCT06623422	Map
CO	Banner MD Anderson Cancer Center at North Colorado Medical Center ( Site 0207)	Greeley80631	NCT06623422	Map
CO	Urology Associates ( Site 0144)	Littleton80122	NCT06833073	Map
CO	Centura Health - St. Anthony North Health Campus ( Site 0189)	Westminster80023	NCT06623422	Map
CT	Yale University School of Medicine ( Site 0201)	New Haven06510	NCT06623422	Map
CT	Eastern CT Hematology & Oncology Associates ( Site 0202)	Norwich06360	NCT06623422	Map
DC	George Washington University Medical Faculty Associates ( Site 4064)	Washington D.C.20037	NCT06077760	Map
FL	The Oncology Institute of Hope and Innovation - Fort Lauderdale ( Site 0156)	Fort Lauderdale33316	NCT06623422	Map
FL	Urological Research Network ( Site 0133)	Hialeah33016	NCT06833073	Map
FL	Mayo Clinic Florida ( Site 4043)	Jacksonville32224	NCT06077760	Map
FL	Miami Cancer Institute at Baptist Health, Inc. ( Site 0214)	Miami33176	NCT06623422	Map
FL	Miami Cancer Institute at Baptist Health, Inc. ( Site 4047)	Miami33176	NCT06077760	Map
FL	Mid Florida Hematology and Oncology Center ( Site 0014)	Orange City32763	NCT06077760	Map
FL	AdventHealth Orlando-AdventHealth Medical Group Hematology & Oncology at Orlandoc ( Site 0013)	Orlando32804	NCT06077760	Map
FL	Moffitt Cancer Center ( Site 0021)	Tampa33612	NCT07221474	Map
FL	Moffitt Cancer Center ( Site 0078)	Tampa33612	NCT06077760	Map
GA	Southeastern Regional Medical Center ( Site 0098)	Newnan30265	NCT06077760	Map
ID	Beacon Cancer Care ( Site 0127)	Post Falls83854	NCT06623422	Map
IL	The University of Chicago Medical Center ( Site 0118)	Chicago60637	NCT06623422	Map
IL	Associated Urological Specialists - Chicago Ridge ( Site 0139)	Chicago Ridge60415	NCT06833073	Map
IL	Illinois Cancer Care ( Site 7003)	Peoria61615	NCT06077760	Map
IA	University of Iowa-Holden Comprehensive Cancer Center ( Site 0062)	Iowa City52242	NCT06077760	Map
KY	Saint Elizabeth Healthcare ( Site 0092)	Edgewood41017	NCT06077760	Map
KY	The University of Louisville, James Graham Brown Cancer Center ( Site 0037)	Louisville40202	NCT06077760	Map
LA	LSU Health Baton Rouge North Clinic ( Site 4040)	Baton Rouge70805	NCT06077760	Map
LA	Our Lady of the Lake RMC-Clinical Research ( Site 4050)	Baton Rouge70808	NCT06077760	Map
LA	Southern Urology, LLC ( Site 0145)	Lafayette70508	NCT06833073	Map
MD	Maryland Oncology Hematology (MOH) ( Site 8102)	Rockville20850	NCT06623422	Map
MA	Dana Farber Cancer Hospital ( Site 0155)	Boston02215	NCT06623422	Map
MA	Massachusetts General Hospital ( Site 0136)	Boston02114	NCT06623422	Map
MI	University of Michigan Clinical Trials Office ( Site 0058)	Ann Arbor48109	NCT06077760	Map
MI	Cancer and Hematology Centers of Western Michigan ( Site 4003)	Grand Rapids49503	NCT06077760	Map
MO	University of Missouri Health Care ( Site 0126)	Columbia65212	NCT06833073	Map
MO	Washington University School of Medicine ( Site 0024)	St Louis63110	NCT07221474	Map
MT	Billings Clinic ( Site 3255)	Billings59101	NCT07513376	Map
NE	NHO Revive Research Institute, LLC ( Site 0137)	Lincoln68506	NCT06833073	Map
NE	NHO Revive Research Institute, LLC ( Site 3218)	Lincoln68506	NCT07513376	Map
NE	NHO Revive Research Institute, LLC ( Site 4009)	Lincoln68506	NCT06077760	Map
NV	Renown Regional Medical Center-Renown Health Medical Oncology ( Site 3207)	Reno89502	NCT07513376	Map
NJ	Memorial Sloan Kettering - Basking Ridge ( Site 4056)	Basking Ridge07920	NCT06077760	Map
NJ	John Theurer Cancer Center at Hackensack University Medical Center ( Site 0036)	Hackensack07601	NCT06077760	Map
NJ	John Theurer Cancer Center at Hackensack University Medical Center ( Site 4047)	Hackensack07601	NCT06961006	Map
NJ	Memorial Sloan Kettering - Monmouth ( Site 4057)	Middletown07748	NCT06077760	Map
NJ	Memorial Sloan Kettering - Bergen ( Site 4059)	Montvale07645	NCT06077760	Map
NJ	Atlantic Health Morristown Medical Center ( Site 4018)	Morristown07960	NCT06077760	Map
NJ	Valley Health Systems - Ridgewood Campus ( Site 0010)	Paramus07652	NCT07221474	Map
NY	New York Oncology Hematology, P.C. ( Site 4012)	Albany12206	NCT06077760	Map
NY	Roswell Park Cancer Institute ( Site 0184)	Buffalo14263	NCT06623422	Map
NY	Memorial Sloan-Kettering Cancer Center at Commack ( Site 4055)	Commack11725	NCT06077760	Map
NY	Hematology-Oncology Associates of CNY ( Site 0164)	East Syracuse13057	NCT06623422	Map
NY	Memorial Sloan Kettering - Westchester ( Site 4058)	Harrison10604	NCT06077760	Map
NY	Perlmutter Cancer Center at NYU Langone Hospital - Long Island-Clinical Research Department ( Site 0095)	Mineola11501	NCT06077760	Map
NY	Icahn School of Medicine at Mount Sinai ( Site 0034)	New York10029	NCT06077760	Map
NY	Icahn School of Medicine at Mount Sinai ( Site 0116)	New York10029	NCT06623422	Map
NY	Laura and Isaac Perlmutter Cancer Center ( Site 0010)	New York10016	NCT06077760	Map
NY	Laura and Isaac Perlmutter Cancer Center at NYU Langone Health ( Site 0111)	New York10016	NCT06833073	Map
NY	Memorial Sloan Kettering Cancer Center ( Site 0029)	New York10065	NCT06077760	Map
NY	Memorial Sloan Kettering Cancer Center ( Site 0137)	New York10065	NCT06623422	Map
NY	The Blavatnik Family- Chelsea Medical Center at Mount Sinai ( Site 0216)	New York10011	NCT06623422	Map
NY	The Blavatnik Family- Chelsea Medical Center at Mount Sinai ( Site 4053)	New York10011	NCT06077760	Map
NY	SUNY Upstate Cancer Center ( Site 0140)	Syracuse13210	NCT06623422	Map
NY	Montefiore Medical Center ( Site 0160)	The Bronx10461	NCT06623422	Map
NY	Montefiore Medical Center- Montefiore Medical Park-Oncology ( Site 0080)	The Bronx10461	NCT06077760	Map
NY	Memorial Sloan Kettering - Nassau ( Site 4060)	Uniondale11553	NCT06077760	Map
NY	Westchester Medical Center ( Site 0196)	Valhalla10595	NCT06623422	Map
NC	Novant Health Weisiger Cancer Insititute ( Site 0266)	Charlotte28204	NCT06623422	Map
NC	Novant Health Weisiger Cancer Insititute ( Site 4052)	Charlotte28204	NCT06077760	Map
NC	Novant Health Forsyth Medical Center ( Site 0166)	Winston-Salem27103	NCT06623422	Map
NC	Novant Health Oncology Specialists ( Site 4045)	Winston-Salem27103	NCT06077760	Map
ND	Sanford Fargo Medical Center-Roger Maris Cancer Center ( Site 0063)	Fargo58102	NCT06077760	Map
ND	Altru Health System ( Site 0040)	Grand Forks58201	NCT06077760	Map
ND	Altru Health System ( Site 3254)	Grand Forks58201	NCT07513376	Map
OH	TriState Urologic Services PSC Inc. dba The Urology Group ( Site 0122)	Cincinnati45212	NCT06833073	Map
OH	University of Cincinnati Medical Center ( Site 0119)	Cincinnati45219	NCT06623422	Map
OH	Cleveland Clinic - Ohio ( Site 0016)	Cleveland44195	NCT07221474	Map
OH	University Hospitals Cleveland Medical Center ( Site 0023)	Cleveland44106	NCT06077760	Map
OH	OSU Brain and Spine Hospital ( Site 0016)	Columbus43210	NCT06077760	Map
OR	Good Samaritan Regional Medical Center-Samaritan Pastega Regional Cancer Center ( Site 0082)	Corvallis97330	NCT06077760	Map
OR	OHSU Knight Cancer Institute - South Waterfront ( Site 0110)	Portland97239	NCT06833073	Map
PA	MidLantic Urology ( Site 0102)	Bala-Cynwyd19004	NCT06833073	Map
PA	St. Lukes Hospital and Health Network ( Site 0186)	Bethlehem18015	NCT06623422	Map
PA	Thomas Jefferson University - Clinical Research Institute ( Site 0006)	Philadelphia19107	NCT06077760	Map
SC	Medical University of South Carolina-Hollings Cancer Center ( Site 0050)	Charleston29425	NCT06077760	Map
TN	Greco-Hainsworth Centers for Research ( Site 4034)	Chattanooga37421	NCT06077760	Map
TN	The Conrad Pearson Clinic ( Site 0143)	Germantown38138	NCT06833073	Map
TN	The University of Tennessee Medical Center ( Site 3223)	Knoxville37920	NCT07513376	Map
TN	Thompson Cancer Survival Center ( Site 0097)	Knoxville37916	NCT06077760	Map
TN	Thompson Cancer Survival Center ( Site 0168)	Knoxville37916	NCT06623422	Map
TN	Baptist Cancer Center ( Site 4049)	Memphis38120	NCT06077760	Map
TN	Elliston Place Medical Oncology & Hematology ( Site 0215)	Nashville37203	NCT06623422	Map
TN	One Oncology - Tennessee Oncology ( Site 4019)	Nashville37203	NCT06077760	Map
TN	SCRI Oncology Partners ( Site 7001)	Nashville37203	NCT06077760	Map
TN	Tennessee Oncology, PLLC - Elliston Place Plaza Medical Oncology & Hematology ( Site 9000)	Nashville37203	NCT07221474	Map
TX	Texas Oncology - Central/South Texas ( Site 8002)	Austin78745	NCT07221474	Map
TX	Texas Oncology-Austin Central ( Site 0107)	Austin78705	NCT06833073	Map
TX	Urology Austin, PLLC ( Site 0109)	Austin78759	NCT06833073	Map
TX	Texas Oncology - DFW ( Site 8103)	Dallas75246	NCT06623422	Map
TX	UT Southwestern Medical Center ( Site 0061)	Dallas75390	NCT06077760	Map
TX	UT Southwestern Medical Center ( Site 0190)	Dallas75390	NCT06623422	Map
TX	Houston Methodist Cancer Center ( Site 0191)	Houston77030	NCT06623422	Map
TX	MD Anderson Cancer Center ( Site 0150)	Houston77030	NCT06623422	Map
TX	Memorial Hermann Cancer Center ( Site 0172)	Houston77030	NCT06623422	Map
TX	Michael E. DeBakey VA Medical Center ( Site 0197)	Houston77030	NCT06623422	Map
TX	O'Quinn Medical Tower at McNair Campus ( Site 0131)	Houston77030	NCT06623422	Map
TX	The University of Texas Health Science Center at Tyler dba UT Health East Texas HOPE Cancer Center ( Site 0148)	Tyler75701	NCT06623422	Map
VA	Inova Schar Cancer Institute ( Site 0003)	Fairfax22031	NCT06077760	Map
VA	Inova Schar Cancer Institute ( Site 4046)	Fairfax22031	NCT06961006	Map
VA	Virginia Cancer Specialists ( Site 0003)	Fairfax22031	NCT07221474	Map
VA	Virginia Cancer Specialists ( Site 0167)	Fairfax22031	NCT06623422	Map
VA	Virginia Cancer Specialists (VCS) ( Site 4004)	Fairfax22031	NCT06077760	Map
VA	Virginia Oncology Associates (VOA) ( Site 8101)	Norfolk23502	NCT06623422	Map
VA	VCU Health Adult Outpatient Pavillion ( Site 0193)	Richmond23219	NCT06623422	Map
VA	Urology of Virginia ( Site 0125)	Virginia Beach23462	NCT06833073	Map
WA	Fred Hutchinson Cancer Center ( Site 0002)	Seattle98109	NCT06077760	Map
WA	Fred Hutchinson Cancer Center ( Site 4041)	Seattle98109	NCT06961006	Map
WA	Swedish Cancer Institute ( Site 0143)	Seattle98104	NCT06623422	Map
WA	Swedish Medical Center-Swedish Cancer Institute ( Site 0088)	Seattle98104	NCT06077760	Map
WA	University of Washington - Fred Hutchinson Cancer Center ( Site 0100)	Seattle98195	NCT06833073	Map
WA	Virginia Mason Franciscan Health - St. Michael Cancer Center ( Site 0192)	Silverdale98383	NCT06623422	Map
WV	Edwards Comprehensive Cancer Center ( Site 4015)	Huntington25701	NCT06077760	Map

Intismeran autogene clinical trials at a glance: phase × recruitment status

Phase	recruiting	active not recruiting	terminated	Total
P1/P2		1		1
P2	3	1		4
P2/P3			1	1
P3	3	1		4

Recruiting Intismeran autogene clinical trials (6)

Studies currently enrolling participants. Click any NCT ID to view the trial detail page (eligibility, sites, contacts).

NCT ID	Title	Phase	Indication	Enrollment	Started
NCT07513376	INTerpath-014A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014)	P3	Non-small Cell Lung Cancer	876	May 2026
NCT06623422	MK-3475A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)	P3	Carcinoma, Non-Small-Cell Lung	680	Oct 2024
NCT06077760	INTerpath-002A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002)	P3	Non-small Cell Lung Cancer	868	Dec 2023
NCT06961006	V940A Clinical Study of Intismeran Autogene (V940) and Pembrolizumab (MK-3475) in People With Melanoma (V940-012/INTerpath-012)	P2	Malignant Melanoma	160	May 2025
NCT06833073	V940A Clinical Study of Intismeran Autogene (V940) and BCG in People With Bladder Cancer (V940-011/INTerpath-011)	P2	Urinary Bladder Neoplasms	308	Mar 2025
NCT07221474	INTerpath-13A Study of Intismeran Autogene (V940)/Placebo + Pembrolizumab and Chemotherapy in Metastatic Squamous Non-Small Cell Lung Cancer (V940-013)	P2	Squamous Non-small Cell Lung Cancer	180	Dec 2025

Intismeran autogene clinical trials by indication

Non-small Cell Lung Cancer (2)

NCT	Acronym	Phase	Status	Title
NCT07513376	INTerpath-014	P3	recruiting	A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014)
NCT06077760	INTerpath-002	P3	recruiting	A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002)

Squamous Non-small Cell Lung Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT07221474	INTerpath-13	P2	recruiting	A Study of Intismeran Autogene (V940)/Placebo + Pembrolizumab and Chemotherapy in Metastatic Squamous Non-Small Cell Lung Cancer (V940-013)

Malignant Melanoma (1)

NCT	Acronym	Phase	Status	Title
NCT06961006	V940	P2	recruiting	A Clinical Study of Intismeran Autogene (V940) and Pembrolizumab (MK-3475) in People With Melanoma (V940-012/INTerpath-012)

Urinary Bladder Neoplasms (1)

NCT	Acronym	Phase	Status	Title
NCT06833073	V940	P2	recruiting	A Clinical Study of Intismeran Autogene (V940) and BCG in People With Bladder Cancer (V940-011/INTerpath-011)

Carcinoma, Non-Small-Cell Lung (1)

NCT	Acronym	Phase	Status	Title
NCT06623422	MK-3475	P3	recruiting	A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)

Carcinoma, Squamous Cell (1)

NCT	Acronym	Phase	Status	Title
NCT06295809	INTerpath-007	P2/P3	terminated	A Study of (Neo)Adjuvant Intismeran Autogene (V940) and Pembrolizumab in Cutaneous Squamous Cell Carcinoma (V940-007)

Renal Cell Carcinoma (1)

NCT	Acronym	Phase	Status	Title
NCT06307431	INTerpath-004	P2	active not recruiting	A Study of Adjuvant Intismeran Autogene (V940) and Pembrolizumab in Renal Cell Carcinoma (V940-004).

Bladder Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT06305767	V940	P1/P2	active not recruiting	A Clinical Study of Intismeran Autogene (V940) Treatment and Pembrolizumab in People With Bladder Cancer (V940-005/INTerpath-005)

Melanoma (1)

NCT	Acronym	Phase	Status	Title
NCT05933577	V940	P3	active not recruiting	A Clinical Study of Intismeran Autogene (V940) Plus Pembrolizumab in People With High-Risk Melanoma (V940-001)

Intismeran autogene pivotal trial highlights (Phase 2/3/4)

Phase-2/3/4 studies with named acronyms — the registration-grade trials most cited in label discussions and Wikipedia.

Acronym	NCT	Phase	Status	Indication	Enrollment	PubMed
INTerpath-014	NCT07513376	P3	recruiting	Non-small Cell Lung Cancer	876	—
MK-3475	NCT06623422	P3	recruiting	Carcinoma, Non-Small-Cell Lung	680	—
INTerpath-002	NCT06077760	P3	recruiting	Non-small Cell Lung Cancer	868	—
V940	NCT05933577	P3	active not recruiting	Melanoma	1,089	—
INTerpath-004	NCT06307431	P2	active not recruiting	Renal Cell Carcinoma	272	—
V940	NCT06961006	P2	recruiting	Malignant Melanoma	160	—
V940	NCT06833073	P2	recruiting	Urinary Bladder Neoplasms	308	—
INTerpath-13	NCT07221474	P2	recruiting	Squamous Non-small Cell Lung Cancer	180	—

Terminated and withdrawn Intismeran autogene trials (1)

Studies that ended before completion. Reasons are filed in each trial's ClinicalTrials.gov entry.

NCT06295809terminatedA Study of (Neo)Adjuvant Intismeran Autogene (V940) and Pembrolizumab in Cutaneous Squamous Cell Carcinoma (V940-007)

All Intismeran autogene trials (10)

Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.

NCT ID	Acronym	Title	Phase	Status	Enrollment	Sponsor	Started
NCT07513376	INTerpath-014	A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014)	P3	recruiting	876	Merck Sharp & Dohme LLC	May 2026
NCT06623422	MK-3475	A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)	P3	recruiting	680	Merck Sharp & Dohme LLC	Oct 2024
NCT06077760	INTerpath-002	A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002)	P3	recruiting	868	Merck Sharp & Dohme LLC	Dec 2023
NCT06307431	INTerpath-004	A Study of Adjuvant Intismeran Autogene (V940) and Pembrolizumab in Renal Cell Carcinoma (V940-004).	P2	active not recruiting	272	Merck Sharp & Dohme LLC	Apr 2024
NCT06305767	V940	A Clinical Study of Intismeran Autogene (V940) Treatment and Pembrolizumab in People With Bladder Cancer (V940-005/INTerpath-005)	P1/P2	active not recruiting	230	Merck Sharp & Dohme LLC	Mar 2024
NCT06961006	V940	A Clinical Study of Intismeran Autogene (V940) and Pembrolizumab (MK-3475) in People With Melanoma (V940-012/INTerpath-012)	P2	recruiting	160	Merck Sharp & Dohme LLC	May 2025
NCT06833073	V940	A Clinical Study of Intismeran Autogene (V940) and BCG in People With Bladder Cancer (V940-011/INTerpath-011)	P2	recruiting	308	Merck Sharp & Dohme LLC	Mar 2025
NCT07221474	INTerpath-13	A Study of Intismeran Autogene (V940)/Placebo + Pembrolizumab and Chemotherapy in Metastatic Squamous Non-Small Cell Lung Cancer (V940-013)	P2	recruiting	180	Merck Sharp & Dohme LLC	Dec 2025
NCT05933577	V940	A Clinical Study of Intismeran Autogene (V940) Plus Pembrolizumab in People With High-Risk Melanoma (V940-001)	P3	active not recruiting	1,089	Merck Sharp & Dohme LLC	Jul 2023
NCT06295809	INTerpath-007	A Study of (Neo)Adjuvant Intismeran Autogene (V940) and Pembrolizumab in Cutaneous Squamous Cell Carcinoma (V940-007)	P2/P3	terminated	46	Merck Sharp & Dohme LLC	Apr 2024

Intismeran autogene clinical trials: frequently asked questions

How many Intismeran autogene clinical trials are there?: 10 Intismeran autogene clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 6 are actively recruiting participants.
Are Intismeran autogene clinical trials recruiting in 2026?: Yes — 6 Intismeran autogene trials are actively recruiting in 2026, with 140 U.S. sites across 34 states. See the recruiting trials and the per-state site list further down this page.
What conditions is Intismeran autogene being studied for?: Intismeran autogene is being studied for Non-small Cell Lung Cancer, Carcinoma in Situ, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Malignant Melanoma and 7 more. The trials are grouped by indication on this page.
What phase is Intismeran autogene in?: Intismeran autogene clinical trials span 4 Phase 3, 4 Phase 2. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
Who sponsors Intismeran autogene clinical trials?: The lead sponsor across the most Intismeran autogene trials is Merck Sharp & Dohme LLC. Each trial row links to the full study detail page including sponsor information.

Sources and methodology

Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming Intismeran autogeneas an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.

Last refreshed June 18, 2026.

Related pages on Hipa.ai:

Intismeran autogene overview